Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioCorRx (BICX) FCF Margin (2016 - 2025)

Historic FCF Margin for BioCorRx (BICX) over the last 15 years, with Q3 2025 value amounting to 99.88%.

  • BioCorRx's FCF Margin changed N/A to 99.88% in Q3 2025 from the same period last year, while for Sep 2025 it was 179.02%, marking a year-over-year increase of 50193400.0%. This contributed to the annual value of 14302.07% for FY2024, which is 122234700.0% down from last year.
  • As of Q3 2025, BioCorRx's FCF Margin stood at 99.88%.
  • In the past 5 years, BioCorRx's FCF Margin registered a high of 70.97% during Q2 2025, and its lowest value of 9383.09% during Q1 2024.
  • Its 5-year average for FCF Margin is 3582.35%, with a median of 2910.84% in 2023.
  • Its FCF Margin has fluctuated over the past 5 years, first plummeted by -84005600bps in 2024, then surged by 88718800bps in 2025.
  • BioCorRx's FCF Margin (Quarter) stood at 4757.39% in 2021, then skyrocketed by 89bps to 542.44% in 2022, then crashed by -420bps to 2818.86% in 2023, then tumbled by -33bps to 3754.59% in 2024, then skyrocketed by 97bps to 99.88% in 2025.
  • Its FCF Margin stands at 99.88% for Q3 2025, versus 70.97% for Q2 2025 and 511.21% for Q1 2025.